Navigation Links
Dohmen to Sell Restat, its Pharmacy Benefit Manager (PBM) Division to Catamaran

Milwaukee, WI (PRWEB) August 01, 2013

Catamaran, the industry’s fastest-growing pharmacy benefit manager, will buy Milwaukee, WI-based Restat, from its parent company Dohmen, for $409.5 million in a transaction expected to close in the fourth quarter of 2013, the companies announced today.

Catamaran CEO Mark Thierer said the addition of Restat will create immediate value for clients and members of both organizations. “As one of the largest privately held pharmacy benefit managers, Restat’s core business is perfectly aligned with Catamaran’s. We have a full suite of services that will complement the strengths of Restat to create a unique go-to-market PBM.”

Dohmen CEO Cynthia (Dohmen) LaConte agrees, “Dohmen’s been committed to creating efficiencies in healthcare supply for over 155 years, so it was important for us to partner with a company that could lower prescription drug costs without compromising care. Catamaran has a unique track record of achieving the right balance of scale and service. Joining Catamaran will create an even stronger marketplace offering in cost, clinical capability and customer service.”

LaConte said the sale of Restat is part of Dohmen’s strategic plan to grow and strengthen its life science service offering. “We’ve decided to exit the pharmacy benefit management business so we can focus exclusively on our life science clients. Dohmen has a long history of anticipating transformative change and building better business models to meet it, and our industry is facing a significant paradigm shift from volume to value. We think we’re uniquely positioned to help drug, device and personalized medicine companies make this transition.”

The agreement to sell Restat, was signed by Catamaran and Dohmen on July 31, 2013, and is set to close in the fourth quarter of 2013.

About Dohmen
Founded in 1858, Dohmen is a life science services company dedicated to creating a safer, more effective healthcare supply system. As the trusted partner to more than 600 BioPharma and Medtech innovators, Dohmen propels start-up, mid-tier and Fortune 500 companies with support services that span the commercialization continuum from pre-approval regulatory consulting to in-home patient services. Privately held and conflict free, Dohmen is uniquely positioned to propel personalized healthcare for life science innovators and individuals.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Dohmen’s BioSoteria Calls for Abstracts for its Seventh Annual Pacific Drug Safety Summit (PDSS)
2. Pharmacy Robots Linked to Bacterial Contamination of Drugs
3. A Void In The Independent Pharmacy Industry Leads to Independent Rx Consulting, Powered by OurHelix
4. Second Compounding Pharmacy Shut Down in Massachusetts
5. Company With Links to Meningitis-Linked Pharmacy Recalls All Products
6. Company With Ties to Meningitis-Linked Pharmacy Recalls All Products
7. Owner of Meningitis-Linked Pharmacy Declines to Testify Before Congress
8. Women’s Excellence in Bladder Control Partners with University Compounding Pharmacy in Troy, MI to Help Women with Chronic Pelvic Pain Conditions
9. Pharmacy researcher finds most popular weight-loss drug strongly alters other drug therapies
10. Unveils PhenObestin 37.5 to Offset Obesity Effectively
11. FDA, States Weigh Pharmacy Regulation in Wake of Meningitis Outbreak
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... Aliso Viejo, CA (PRWEB) , ... November 26, ... ... X users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. ... custom style options. These classically-influenced trailer titles work with any font, giving users ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology: